MEP14408A - 4- halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja - Google Patents

4- halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja

Info

Publication number
MEP14408A
MEP14408A MEP-144/08A MEP14408A MEP14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A
Authority
ME
Montenegro
Prior art keywords
compounds
production
pharmaceutical compositions
compositions containing
halogenated
Prior art date
Application number
MEP-144/08A
Other languages
English (en)
Inventor
Bernd Menzenbach
Walter Elger
Peter Droescher
Alexander Hillisch
Guenter Kaufmann
Hans-Udo Schweikert
Gerd Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MEP14408A publication Critical patent/MEP14408A/bs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pronalazsak se odnosi na 17-metilen steroide, postupak za njihovu proizvodnju i farmaceutske sastave koji sadrže ova jedinjenja. Jedinjenja u skladu sa pronalasakom imaju profil dejstva hibridnog tipa u smislu da se ponašaju kao inhibitori 5α-reduktaze i simultano kao gestageni. Oni su zbog toga pogodni za liječenje bolesti koje su rezultat povišenih nivoa androgena u određenim organima i tkivima kod muškaraca i žena. Zajedno sa drugim hormonalnim supstancama, kao što su estrogen, testosteron, ili jaki androgen, jedinjenja u skladu sa pronalaskom su pogodna kao kontraceptivna sredstva za žene i muškarce.
MEP-144/08A 2000-09-04 2001-08-29 4- halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja MEP14408A (bs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (de) 2000-09-04 2000-09-04 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
PCT/EP2001/009943 WO2002019971A1 (de) 2000-09-04 2001-08-29 4-halogenierte 17-methylensteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Publications (1)

Publication Number Publication Date
MEP14408A true MEP14408A (bs) 2010-06-10

Family

ID=7655148

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-144/08A MEP14408A (bs) 2000-09-04 2001-08-29 4- halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja

Country Status (28)

Country Link
EP (1) EP1423407B1 (bs)
JP (1) JP2004513084A (bs)
KR (1) KR100530816B1 (bs)
CN (1) CN1262560C (bs)
AT (1) ATE319733T1 (bs)
AU (2) AU1047002A (bs)
BG (1) BG107594A (bs)
BR (1) BR0113618A (bs)
CA (1) CA2421302C (bs)
DE (2) DE10043846A1 (bs)
DK (1) DK1423407T3 (bs)
EA (1) EA006387B1 (bs)
EE (1) EE05186B1 (bs)
ES (1) ES2260294T3 (bs)
HR (1) HRP20030256A2 (bs)
HU (1) HUP0300936A3 (bs)
IL (2) IL154666A0 (bs)
ME (1) MEP14408A (bs)
MX (1) MXPA03001912A (bs)
NO (1) NO325012B1 (bs)
NZ (1) NZ524485A (bs)
PL (1) PL360669A1 (bs)
PT (1) PT1423407E (bs)
RS (1) RS50305B (bs)
SK (1) SK286757B6 (bs)
UA (1) UA74592C2 (bs)
WO (1) WO2002019971A1 (bs)
ZA (1) ZA200301715B (bs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (de) 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
AT12800U1 (de) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
AU2001268661A1 (en) * 2000-06-27 2002-01-08 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
PT1423407E (pt) 2006-07-31
IL154666A0 (en) 2003-09-17
EP1423407A1 (de) 2004-06-02
ZA200301715B (en) 2004-08-13
NZ524485A (en) 2005-11-25
EE05186B1 (et) 2009-06-15
SK2442003A3 (en) 2003-08-05
WO2002019971A1 (de) 2002-03-14
EA006387B1 (ru) 2005-12-29
UA74592C2 (en) 2006-01-16
CA2421302C (en) 2007-08-14
ATE319733T1 (de) 2006-03-15
NO20030989L (no) 2003-05-02
MXPA03001912A (es) 2004-07-08
BR0113618A (pt) 2003-07-15
BG107594A (bg) 2003-09-30
YU16403A (sh) 2006-05-25
DK1423407T3 (da) 2006-07-03
CN1262560C (zh) 2006-07-05
EP1423407B1 (de) 2006-03-08
JP2004513084A (ja) 2004-04-30
AU2002210470B2 (en) 2006-07-20
KR100530816B1 (ko) 2005-11-25
HRP20030256A2 (en) 2005-10-31
RS50305B (sr) 2009-09-08
KR20030028836A (ko) 2003-04-10
NO325012B1 (no) 2008-01-14
DE10043846A1 (de) 2002-04-04
PL360669A1 (en) 2004-09-20
HUP0300936A2 (hu) 2003-11-28
HK1060135A1 (en) 2004-07-30
EA200300322A1 (ru) 2003-10-30
CN1452628A (zh) 2003-10-29
IL154666A (en) 2008-12-29
SK286757B6 (sk) 2009-05-07
NO20030989D0 (no) 2003-03-03
ES2260294T3 (es) 2006-11-01
EE200300087A (et) 2005-02-15
CA2421302A1 (en) 2003-03-03
DE50109175D1 (de) 2006-05-04
HUP0300936A3 (en) 2010-01-28
WO2002019971A9 (de) 2002-08-08
AU1047002A (en) 2002-03-22

Similar Documents

Publication Publication Date Title
NO20091190L (no) Fremgangsmater og sammensetninger for behandling av kreft
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
BR112012009306A2 (pt) método para regeneração de mielina em um paciente
ID26781A (id) Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer
ZA200203439B (en) Novel tropical oestroprogestational compositions with systemic effect.
MX2019001323A (es) Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
DE50112128D1 (de) Retardpartikeldispersion
Mutiah et al. Cytotoxic effect of crude extract and fraction from Calotropis gigantea leaves on human colon cancer widr cell lines
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
NZ760155A (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
NO20023276L (no) Fremgangsmåter fremstilling av betulinsyre
IL164159A0 (en) C-17 spirolactonization and 6,7 oxidation of steroids
SG158916A1 (en) Nitrooxy derivatives op glucocorticoids
ES2166549T3 (es) Procedimiento de preparacion de 17-esteres de 9alfa,21-dihalo-pregnan-11beta,17alfadiol-20-onas.
NO20053626L (no) Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose
EE05186B1 (et) 4-halogeenitud-17-metleensteroidid, nende valmistamismeetod ja neid hendeid sisaldavad farmatseutilised kompositsioonid
DK1200107T3 (da) Præparater der har steroid östrogenvirkning, hvilke præparater ikke öger risikoen for brystcancer
AR048829A1 (es) 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos.
EA201001006A1 (ru) γ-ЛАКТОНОВОЕ ПРОИЗВОДНОЕ СТЕРОИДА 15,16-МЕТИЛЕН-17-ГИДРОКСИ-19-НОР-21-КАРБОНОВОЙ КИСЛОТЫ, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, СОДЕРЖАЩИЕ ПРОИЗВОДНОЕ
ATE470669T1 (de) D-(17alpha)-13-ethyl-17hydroxy-18,19-dinorpregn 4-ene-20-yne-3-one in form des reinen 3e- und 3z- oximes sowie das verfahren zur herstellung der mischung der isomere wie auch der reinen isomere
ES2150996T3 (es) Corticoides y composiciones farmaceuticas y cosmeticas.
DK1910398T3 (da) 17-alfa-substituerede derivater af estradiol med sårhelende virkning
AR003967A1 (es) Epimeros de (22r)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-oxo-4-aza-5alfa- androst-1-eno-17beta-carboxamida, un proceso para su preparacion y unacomposicion farmaceutica que los comprenden.